Mechanisms of asthma and allergic inflammation
Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts

https://doi.org/10.1016/j.jaci.2006.08.028Get rights and content

Background

Cysteinyl leukotrienes (cys-LTs) are potent asthma-related mediators that function through their G protein–coupled receptors, cys-LT receptor type 1 (CysLT1R) and cys-LT receptor type 2 (CysLT2R).

Objective

Because many G protein–coupled receptors transactivate the epidermal growth factor receptor (EGFR) through metalloprotease-mediated ligand shedding, we investigated the effects of cys-LTs on signal transduction and proliferation of bronchial fibroblasts.

Methods

Human bronchial fibroblasts were grown from biopsy specimens of healthy subjects. Mitogenesis was assessed on the basis of tritiated methylthymidine incorporation.

Results

Leukotriene (LT) D4 alone did not increase mitogenesis but dose-dependently increased thymidine incorporation and cell proliferation in the presence of epidermal growth factor (EGF). The enhancement was not prevented by CysLT1R antagonists (MK-571 and montelukast) or by a dual antagonist (BAY u9773), which is consistent with the lack of detectable mRNA for CysLT1R and CysLT2R in bronchial fibroblasts. LTD4 did not cause EGFR transphosphorylation nor was the synergism blocked by the metalloprotease inhibitor GM6001. The EGFR-selective kinase inhibitor AG1478 suppressed the synergy between LTD4 and EGF but had no effect on synergistic interactions of LTD4 with other receptor tyrosine kinase growth factors. The effect of LTD4 involved a pertussis toxin–sensitive and protein kinase C–mediated intracellular pathway, leading to sustained growth factor–dependent phosphorylation of extracellular signal–regulated kinase 1/2 and protein kinase B (PKB/Akt).

Conclusion

Cys-LTs do not transactivate EGFR but have a broader capability to synergize with receptor tyrosine kinase pathways.

Clinical implications

This study implies a critical role of cys-LTs in airway fibrosis in asthma and other chronic airway diseases, which might not be blocked by therapy with current LT receptor antagonists.

Section snippets

Cell cultures

Primary human bronchial fibroblasts were grown from bronchial biopsy specimens obtained from healthy subjects, as previously reported.16 The detailed methods are described in the Methods section in the Online Repository at www.jacionline.org.

Reagents

LTD4, LTC4, and MK-571 were from Cayman Chemical (Ann Arbor, Mich). Montelukast sodium was a kind gift from Dr Jilly Evans (Merck, West Point, Pa). Other reagents are described in the Methods section in the Online Repository at www.jacionline.org.

Mitogenesis analyses

Bronchial

LTD4 synergizes with EGF to induce mitogenesis

To assess whether cys-LTs have mitogenic activity, we analyzed the incorporation of tritiated thymidine into primary cultures of bronchial fibroblasts. LTC4 or LTD4 alone had little mitogenic effect. However, when coincubated with EGF, both LTC4 and LTD4 dose-dependently augmented EGF-induced mitogenesis. Thus 0.5 μmol/L of LTD4 or LTC4 increased mitogenesis by 408% ± 93% (P = .002) or 421% ± 97% (P = .002), respectively, compared with EGF (1 ng/mL) alone. The dose-response curves show very

Discussion

Airway remodeling is an important component of chronic asthma involving proliferation and activation of airway fibroblasts.20 Previous studies have shown that LTC4 and LTD4 stimulate mitogenesis of human skin fibroblasts in vitro.21 Furthermore, targeted deletion of the CysLT1R gene unexpectedly augmented bleomycin-induced lung fibrosis and alveolar septal thickening,22 whereas deletion of CysLT2R prevented these effects.23 These data suggest that CysLT1R and CysLT2R have distinct functions

References (33)

  • E. Pizzichini et al.

    Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

    Eur Respir J

    (1999)
  • W.R. Henderson et al.

    A role of for cysteinyl leukotrienes in airway remodeling in a mouse asthma model

    Am J Respir Crit Care Med

    (2002)
  • K. Parameswaran et al.

    The effect of pranlukast on allergen-induced bone marrow eosinophilopoiesis in subjects with asthma

    Am J Respir Crit Care Med

    (2004)
  • J. Christian Virchow et al.

    The Zafirlukast Study Group. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

    Am J Respir Crit Care Med

    (2000)
  • C.G. Löfdahl et al.

    Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

    BMJ

    (1999)
  • M. Salmon et al.

    Involvement of cysteinyl leukotrienes in airway smooth muscle cell DNA synthesis after repeated allergen exposure in sensitized Brown Norway rats

    Br J Pharmacol

    (1999)
  • Cited by (41)

    • Leukotriene D<inf>4</inf> role in allergic asthma pathogenesis from cellular and therapeutic perspectives

      2020, Life Sciences
      Citation Excerpt :

      Fibroblasts located in the peripheral airways express higher levels of CysLT1R compared to the one in the central airways, and these expression level doesn't differ between asthmatics and non-asthmatics [106]. Although LTD4 alone doesn't have an effect on primary human bronchial fibroblasts proliferation, it can synergize with other growth factors including EGF, PDGF, and FGF to potentiate cell proliferation through a PKC-mediated intracellular pathway, leading to a sustained growth factor-dependent phosphorylation of Erk-1/2 and Akt [107]. LTD4 potentiates the TGFβ1-mediated secretion of collagen in human fetal lung fibroblasts.

    • Lipid mediator Leukotriene D<inf>4</inf>-induces airway epithelial cells proliferation through EGFR/ERK1/2 pathway

      2018, Prostaglandins and Other Lipid Mediators
      Citation Excerpt :

      Studies have suggested that GPCRs such as CysLT receptors require growth factor receptors and their tyrosine kinase activity to induce mitogenic effects [9,18]. The CysLT receptors have broader capacity to synergize with other receptor tyrosine kinases (RTKs) and not necessarily transactivate EGFR [10]. We also found that LTD4 caused EGFR phosphorylation concentration-dependently in SAECs and A549 cells which was increased by EGF, though non-significantly, suggesting that the effect of two stimulants could be mediated through EGFR activation (Fig. 4A & B and D & E, respectively), which leads to increased ERK1/2 phosphorylation and activation.

    • The epidermal growth factor receptor inhibitor AG1478 inhibits eosinophilic inflammation in upper airways

      2018, Clinical Immunology
      Citation Excerpt :

      Ligand-shedding dependent transactivation of the EGFR is mediated by ligands such as amphiregulin and TGF-α, which are cleaved from their membrane-anchored forms by activated metalloproteinase. Although important roles of EGFR signaling have been reported in bronchial and alveolar fibroblasts [33,34], this is the first report to show inhibitory effects of the EGFR inhibitor AG1478 on cytokine secretion from nasal fibroblasts. Mucus hypersecretion and eosinophil infiltration are common characteristics of allergic airway inflammation [3].

    • Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B<inf>2</inf> receptor and different MAPK pathways

      2013, European Journal of Pharmacology
      Citation Excerpt :

      In some experiments, cells were pre-incubated with bradykinin B2 receptor antagonist HOE140 (1 μM; 15 min; Sigma-Aldrich) before exposure to bradykinin. The signaling pathways involved in bradykinin-induced HABFb and HNBFb functions were investigated using the specific inhibitors (1 h pretreatment): U0126 (1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene) at 10 µM (for ERK1/2; Sigma-Aldrich) (Davies et al., 2000; Kuang et al., 2007), SB203580 (4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine) at 10 µM (for p38 MAPK; Sigma-Aldrich) (Davies et al., 2000; Han et al., 2009), AG1478 (N-(3-chlorophenyl)-6,7-dimethoxy-4-quinazolinanine) at 1 µM (for EGF receptor; Sigma-Aldrich) (Puri et al., 2008; Tsukagoshi et al., 2002), and GM6001 (N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-l-tryptofan methylamine) at 20 µM (for metalloproteinases; Inalco S.p.A, Milan, Italy) (Devel et al., 2012; Yoshisue et al., 2007). ERK1/2 and p38 activation were evaluated in fibroblasts stimulated with bradykinin (10−11 or 10−6 M) for 5 min.

    View all citing articles on Scopus

    Supported by Asthma UK.

    Disclosure of potential conflict of interest: H. Yoshisue and D. E. Davies have received grant support from Asthma UK. A. P. Sampson has consultant arrangements with Merck Sharp & Dohme; has received grant support from Merck & Co, Ono Pharma UK Ltd, and AstraZeneca; and has received honoraria from Merck & Co. The rest of the authors have declared that they have no conflict of interest.

    View full text